(Boursier.com) — Eurobio Scientific recorded in the 1st half of 2022 a turnover of 83.6 ME against 95.7 ME in the 1st half of 2021 (-13%) which had been very marked by the new epidemic waves linked to COVID-19.
Eurobio benefited from a growth of +5.1% in its turnover excluding COVID to 43 ME in the 1st half of 2022 against 40.9 ME in the 1st half of 2021 while COVID sales decreased to 40.6 ME against EUR54.8m (-26%).
COVID revenue was marked by a sharp drop in sales prices and test volumes, partially offset by the extension of the product portfolio with specific tests for the characterization of SARS-Cov-2 virus variants.
Eurobio Scientific currently has gross cash in excess of 115 ME, for a financial debt of 13.8 ME. “These financial resources, combined with a strengthening of its human resources, particularly in R&D, support the strategic deployment, focused on increasing the share of proprietary products, the pursuit of international expansion, and the opening of new market segments”, underlines the group.
©2022 Boursier.com